

Gastrointestinal (GI) Disease-Oriented Team

Clinical Research Treatment Trial Flowchart



NEOADJUVANT

A022104/Janus Trial
(Triplet vs. double chemo)

Coord: A. Luna
PI: Dr. Zell
Accrual: 1/5

EA2201
(Nivo + Ipi + radiation)

Coord: K. Ghio
PI: Dr. Valerin
Accrual: 0/3

UCI 21-67
(Epacadostat + short course radiation + chemo)

PI: Dr. Valerin
Pending IRB, budget, contract

ADJUVANT

NRG-GI008/CIRCULATE
(ctDNA guided tx)

Coord: A. Luna
PI: Dr. Zell
Accrual: 1/5

NRG-GI005/COBRA
(SOC vs mFOLFOX6 or CAPOX or surveillance)

Coord: LM Aguilar
PI: Dr. Zell
Accrual: 2/5

INTRA-OPERATIVE

UCI 20-163
(SOC vs CG-100 Intraluminal)

Coord: M. Nguyen
PI: Dr. Carmichael
Accrual: 2/10
Bypass Device

MOLECULAR FAILURE

UCI 20-43
(TAS102 + irinotecan)

Coord: K. Ghio
PI: Dr. Dayyani
Accrual: 4/11

1L METASTATIC

UCI 22-07
(BXQ-350 + mFOLFOX7
and bevacizumab)

Coord: A. Luna
PI: Dr. FC Lee
Accrual: 2/5

UCI 21-110
(only EC naïve patients
with BRAFV600E CRC)
Encorafenib + cetuximab
+ ERAS-007

Coord: P. Yang
PI: Dr. Dayyani
Accrual: 6/15

A022101
(at least 4 months of
chemo once metastatic
disease is confirmed)

Coord: A. Luna
PI: Dr. Eng
Accrual: 0/2

2L METASTATIC**S2107**

(Encorafenib + cetuximab +/- nivo)

Coord: LM Aguilar

PI: Dr. Valerin
Accrual: 0/3

UCI 22-87
(KRAS inhibitor)

Coord: LM Aguilar
PI: Dr. Ou
Accrual: 12/20

UCI 22-131
(XL092 +
atezolizumab vs.
regorafenib)

Coord: P. Yang
PI: Dr. Dayyani
Accrual: 6/10

UCI 21-39
(Pembro + TATE)

Coord: LM Aguilar
PI: Dr. Abi-Jaoudeh
Accrual: 19/30

UCI 20-84
(HES vs. SOC TACE)

Coord: M. Duron
PI: Dr. Abi-Jaoudeh
Accrual: 8/13

UCI 21-208
(nti-DR5 targeting pentameric Igm antibody IGM-8444)

Coord: M. Nguyen

PI: Dr. Chow
Accrual: 6/8



Newly Diagnosed

[ECOG-EA2182](#)
(Mitomycin-C + 5-Fluorouracil +
Capecitabine)

Coord: J. Koff
PI: Dr. Zell
Accrual: 1/3

Advanced/Metastatic

[ECOG-EA2176](#)
(Nivolumab + Carboplatin +
Paclitaxel)

Coord: J. Koff
PI: Dr. Valerin
Accrual: 3/5

Neoadjuvant

UCI 21-191

(SOC therapy with ctDNA testing)

Coord: A. Luna
PI: Dr. Dayyani
Pending activation

Newly Diagnosed Metastatic

UCI 20-87

(V Paclitaxel + IV 5-FU + IV leucovorin + IP paclitaxel)

Coord: L. Mejia
PI: Dr. Senthil
Accrual: 19/20

UCI 22-76

(Anti-PD-1 + chemo +/- anti-TIGIT)

Coord: J. Koff
PI: Dr. Dayyani
Accrual: 1/10

UCI 21-193

(FGFR inhibitor + mFOLFOX6 + antiPD-L1 (nivolumab))

Coord: J. Koff
PI: Dr. Dayyani
Accrual: 1/12

A022102

(mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab)

Coord: J. Koff
PI: Dr. Dayyani
Accrual: 1/7

EA2183

(SOC + XRT)

Coord: J. Koff
PI: Dr. Seyedin
Accrual: 0/7

Recurrent

UCI 23-78

(EGFR and MET-directed antibody)

Coord: J. Koff
PI: Dr. Dayyani
Accrual: 0/3

UCI 16-94

(Tirapazamine, Nivolumab)

Coord: LM Aguilar
PI: Dr. Abi-Jaoudeh
Accrual: 24/40

UCI 23-109

(Disitamab Vedotin + Tucatinib)

Coord: TBD
PI: Dr. Dayyani
Pending activation

UCI 22-51

(ASP2138)

Coord: LM Aguilar
PI: Dr. Dayyani
Accrual: 0/10

(Bispecific antibody (anti-CLDN18.2 + anti-4-1BB))

Coord: K. Ghio
PI: Dr. Dayyani
Accrual: 10/17

Advanced Solid Tumors By Biomarker

HER-2

UCI 20-67

nti-PD-1 DF1001
(monotherapy or
combination
therapy)

Coord: M. Nguyen

PI: Dr. Valerin
Accrual: 18/20

ETCTN-10358/DASH

(DS8201a +
AZD6738)

Coord: M. Nguyen

PI: Dr. Dayyani
Accrual: 0/3

UCI 21-57

(Bispecific antibody
(anti-HER2) + CD47-
blocking infusion
protein)

Coord: A. Chavez
PI: Dr. Parajuli
Accrual: 4/5

ETCTN-10495

(DS-8201a +
Neratinib)

Coord: M Nguyen

PI: Dr. Dayyani
Accrual: 0/7

BRAF

S2107

(Encorafenib +
cetuximab +/- nivo)

Coord: LM Aguilar

Dr. Valerin
Accrual: 0/3

Open to Accrual

KRAS

UCI 22-88

(Tri-complex
inhibitor KRAS^{G12C}
(ON) and
NRAS^{G121C}(ON))

Coord: R. Chang

PI: Dr. Ou
Accrual: 3/25

UCI 21-53

RAS-G12C inhibitor)

Coord: J. Choe

PI: Dr. Nagasaka
Accrual: 6/8

UCI 22-87 (KRAS inhibitor)

Coord: LM Aguilar
PI: Dr. Ou
Accrual: 9/20

Low Accruing

EGFR

UCI 22-171

(Anti-PD-1 +/- DF9001)

Coord: M. Nguyen
PI: Dr. Valerin
Accrual: 3/15

Pending Activation/Suspended

CLDN18.2

UCI 21-10

(Bispecific antibody
(anti-CLDN18.2 +
anti-4-1BB))

Coord: K. Ghio

PI: Dr. Dayyani
Accrual: 10/17

(ASP2138)

Coord: LM Aguilar
PI: Dr. Dayyani

Accrual: 0/10



Advanced Solid Tumor

UCI 23-85
(BA3182 +
(EPCAM)/CD3
Antibody)
Coord: TBD
PI: Dr. Valerin
Accrual: 0/5

UCI 21-146
(Anti-Tissue Factor
monoclonal
antibody-
BCNvcMMAE
conjugate)
Coord: C. Kang
PI: Dr. Dayyani
Accrual: 5/11

ETCTN-10579
(ZEN003694 (ZEN-
3694) +
capecitabine)
Coord: P. Yang
Accrual: 0/4

UCI 22-37
(Inhibitor of KDM4
histone
demethylase)
Coord: A. Luna
PI: Dr. Dayyani
Accrual: 4/10

UCI 22-26
(Androgen and
glucocorticoid
receptor
antagonist)
Coord: N. Ferrand
PI: Dr. Dayyani
Accrual: 7/12

UCI 22-221
BiTe of B7-H6
(Central B7-H6 testing)
HCC and Pancreatic
(also NSCLC, HNSCC,
CRC, and gastric)
Coord: P. Yang
PI: Dr. Dayyani
Accrual: 2/12



UCI 03-03
(Immunologic response analysis)

Coord: B. Sanchez
PI: Dr. Imagawa
Accrual: 262/400

UCI 20-101
(Biospecimen Collection for patients planned to start treatment)

Coord: N. Arechiga
PI: Dr. Senthil
Accrual: 53/80

UCI 23-21
(Exosome Gene Expression Peritoneal Fluid&Plasma in Gastrointestinal Malignancies)

Coord: LM Aguilar
PI: Dr. Senthil
Accrual: 0/70

UCI 20-04
(Tissue Collection)

Coord: B. Sanchez
PI: Dr. Dayyani
Accrual: 98/130

UCI 22-109
alonosteron buccal film vs. IV Palonosetron)

Coord: P. Yang
PI: Dr. Dayyani
Accrual: 1/30